Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Sees Large Decrease in Short Interest

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) saw a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 136,400 shares, a drop of 27.9% from the November 15th total of 189,100 shares. Based on an average daily trading volume, of 558,700 shares, the days-to-cover ratio is currently 0.2 days. Currently, 7.6% of the shares of the company are sold short.

Lixte Biotechnology Stock Performance

Shares of NASDAQ LIXT traded up $0.08 during midday trading on Friday, hitting $1.99. The company’s stock had a trading volume of 1,259 shares, compared to its average volume of 321,904. Lixte Biotechnology has a 1-year low of $1.31 and a 1-year high of $4.40. The firm’s fifty day moving average price is $1.84 and its 200-day moving average price is $2.06. The firm has a market cap of $4.47 million, a P/E ratio of -1.16 and a beta of -0.11.

Lixte Biotechnology Company Profile

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.